Clearside Biomedical (CLSD) IPO Opens Up 14%

Go back to Clearside Biomedical (CLSD) IPO Opens Up 14%

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

June 1, 2016 11:15 PM UTC

ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share.  In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000 shares of common stock at the public offering price, less underwriting discounts and commissions.  The shares are scheduled to begin trading on the NASDAQ Global... More